不同新辅助放疗剂量对局部晚期直肠癌生存与毒性的影响
回顾性分析247例局部晚期中低位直肠癌患者,比较PGTV 50.4 Gy/24次与PTV 45.6 Gy/24次方案(实验组)与PTV 50 Gy/25次方案(对照组)。实验组≥3级急性不良反应和围手术期并发症显著更低,预防性回肠造口还纳率更高,短期疗效与3年生存结局无显著差异。
要点
- 实验组盆腔淋巴引流区剂量降低至45.6 Gy/24次,≥3级急性不良反应显著减少。
- 两组pCR率、括约肌保留率、TRG分级及3年OS、PFS、DFS、MFS、LRFS无显著差异。
- 实验组围手术期并发症更少、预防性回肠造口还纳率更高,无围手术期死亡。
核心结论
- 实验组降低盆腔淋巴引流区放疗剂量后,≥3级急性不良反应发生率显著低于对照组,且不损害短期疗效与生存结局。
- 实验组围手术期并发症显著更少,预防性回肠造口还纳率更高,无严重不良事件导致围手术期死亡。
研究设计与样本
- 所有患者接受同步放化疗及根治性全直肠系膜切除术(TME)。
- 实验组:直肠原发肿瘤及转移淋巴结(PGTV)50.4 Gy/24次,盆腔淋巴引流区(PTV)45.6 Gy/24次;对照组:直肠肿瘤及盆腔淋巴引流区(PTV)50 Gy/25次。
主要发现
- 两组pCR率、括约肌保留率、TRG分级、pT及pN降期率以及3年OS、PFS、DFS、MFS、LRFS均无显著差异(P > 0.05)。
- 实验组≥3级急性不良反应发生率显著低于对照组,且无导致围手术期死亡的严重不良事件。
- 实验组围手术期并发症发生率显著更低,预防性回肠造口还纳率更高。
- 两组≥3级晚期不良反应发生率无显著差异。
- 单因素分析显示性别、TRG分级、术后T/N分期、癌结节及基线CEA和CA199水平是影响OS、PFS、DFS、MFS、LRFS的显著因素;多因素分析显示术后T分期、N分期及基线CA199与OS、PFS、DFS、MFS显著相关,术后T分期与LRFS显著相关。
关键数值与推荐
- 实验组PGTV处方剂量为50.4 Gy/24次,PTV为45.6 Gy/24次;对照组PTV为50 Gy/25次。
- 两组pCR率、括约肌保留率、TRG分级、pT和pN降期率及3年OS、PFS、DFS、MFS、LRFS比较P > 0.05。
临床怎么用
- 对于局部晚期中低位直肠癌新辅助放化疗,可考虑降低盆腔淋巴引流区预防性照射剂量至45.6 Gy/24次以减少急性不良反应和围手术期并发症。
- 该剂量方案不损害pCR率、降期率及3年生存结局,且可能提高预防性回肠造口还纳率。
局限性
- 本研究为单中心回顾性分析,样本量247例,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: To investigate the impact of two neoadjuvant radiotherapy regimens on survival outcomes and adverse reactions in patients with locally advanced low and mid rectal cancer. METHODS: A retrospective analysis was conducted on 247 patients with locally advanced rectal cancer, treated at the Department of Radiation Oncology, Liaoning Cancer Hospital, between January 2015 and December 2020. The patients received two different neoadjuvant radiotherapy regimens: In the experimental group, the prescribed radiation dose for the primary rectal tumor and metastatic lymph nodes (PGTV) was 50.4 Gy/24 fractions, and for the pelvic lymphatic drainage area (PTV) was 45.6 Gy/24 fractions. In the control group, the prescribed radiation dose for the rectal tumor and pelvic lymphatic drainage area (PTV) was 50 Gy/25 fractions. The primary endpoints of the study included comparing the two groups in terms of pathological complete response (pCR), anal sphincter preservation rate, 3-year overall survival (OS), 3-year progression-free survival (PFS), acute adverse reactions, perioperative complications, preventive ileostomy reversal rate after LAR, and late adverse reactions. The secondary endpoints included comparing tumor regression grade (TRG), pT downstaging rate, pN downstaging rate, 3-year disease-free survival (DFS), 3-year metastasis-free survival (MFS), and 3-year local recurrence-free survival (LRFS) between the two groups. Univariate and multivariate analyses were performed to identify clinical factors influencing prognosis. RESULTS: This study included 247 patients with locally advanced rectal cancer, all of whom underwent synchronous chemoradiotherapy and radical total mesorectal excision (TME). The experimental group showed comparable results to the control group in terms of pCR rate, anal sphincter preservation rate, TRG grade, pT and pN downstaging rates, as well as 3-year OS, PFS, DFS, MFS, and LRFS (P > 0.05). The experimental group exhibited a significantly lower incidence of ≥ 3 grade acute adverse reactions compared to the control group and had no severe adverse events leading to perioperative mortality. Additionally, the experimental group showed a significantly lower incidence of perioperative complications and a higher preventive ileostomy reversal rate. There were no significant differences between the groups in the incidence of ≥ 3 grade late adverse reactions. Univariate analysis revealed that gender, TRG grade, postoperative T/N stage, cancer nodules, and baseline CEA and CA199 levels were significant factors influencing OS, PFS, DFS, MFS, and LRFS. Multivariate analysis indicated that postoperative T stage, N stage, and baseline CA199 were significantly correlated with OS, PFS, DFS, and MFS, while postoperative T stage was significantly associated with LRFS. CONCLUSIONS: Compared to the control group, the experimental group, which utilized a reduced radiation dose for the pelvic lymphatic drainage area, achieved a significantly lower incidence of ≥ 3 grade acute adverse reactions, fewer perioperative complications, and a higher preventive ileostomy reversal rate without any severe perioperative mortality, thereby enhancing the patients' quality of life, without compromising short-term efficacy or survival outcomes.
引用
- Huang W, Duan X, Hong H, et al. The impact of different neoadjuvant radiotherapy doses on survival outcomes and toxicity in patients with locally advanced rectal cancer. Radiat Oncol. 2025. PMID: 41029429. doi:10.1186/s13014-025-02726-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。